ArticleScientific reports2021
Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05454345 (A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Prostatic Abscess Secondary to Postoperative Wound Infection Caused by Mycobacterium mageritense.Internal medicine (Tokyo, Japan) · 2026Article
- Genetic analysis ofiScience · 2026Article
- Plasmid-mediated macrolide resistance among rapidly growing mycobacteria in Japan.JAC-antimicrobial resistance · 2026Article
- Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes.BMC microbiology · 2025Article
- Evaluation of mlstverse system for accurate subspecies identification and drug resistance prediction inMicrobiology spectrum · 2025Article
- Successful treatment of Keratitis caused by Mycobacterium chelonae and an overview of previous cases in Europe.Annals of clinical microbiology and antimicrobials · 2024Review
- In vitro susceptibility of nontuberculous mycobacteria in China.BMC infectious diseases · 2024Article
- Pharmacological validation of dihydrofolate reductase as a drug target inAntimicrobial agents and chemotherapy · 2024Article
- Drug-drug interactions in the management of non-tuberculous mycobacterial infections.Frontiers in microbiology · 2024Review
- Epidemiology, clinical presentation, and predictors of outcome in nontuberculous mycobacterial central nervous system infection: a systematic review.Tropical medicine and health · 2023Review
- Clinical characteristics and drug susceptibility profiles of Mycobacterium abscessus complex infection at a medical school in Thailand.Annals of clinical microbiology and antimicrobials · 2023Article
- Secondary spontaneous pneumothorax in a patient with resistantRespiratory medicine case reports · 2023Article
- Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate ofFrontiers in cellular and infection microbiology · 2022Article
- Article
- Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?Antibiotics (Basel, Switzerland) · 2021Review
- Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.Microbiology spectrum · 2021Article
- Sitafloxacin Expresses Potent Anti-Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify effective treatments against rapidly growing mycobacteria (RGM) infections by investigating the minimum inhibitory concentrations (MIC) of 24 antimicrobial agents and their molecular mechanisms of resistance. In total, 509 clinical RGM isolates were identified by analyzing the sequences of three housekeeping genes (hsp65, rpoB, and sodA), and their susceptibilities to 24 antimicrobial agents were tested. We also performed sequencing analysis of antimicrobial resistance genes (rrl, rrs, gyrA, and gyrB). To identify Mycobacteroides abscessus group subspecies, we performed PCR-based typing and determined the sequevar of erm(41). We identified 15 RGM species, most of which were susceptible to amikacin and linezolid. Among these species, arbekacin and sitafloxacin had the lowest MIC among the same class of antimicrobials. The MIC of rifabutin for M. abscessus subsp. abscessus (MAB) was lower than that for M. abscessus subsp. massiliense (MMA). The proportion of MAB isolates with MIC ≤ 2 mg/L for rifabutin was significantly higher than that of MMA [MAB: 50/178 (28.1%) vs. MMA: 23/130 (17.7%); p = 0.041]. In summary, our study revealed the antimicrobial susceptibility profile of 15 RGM species isolated in Japan and indicated that arbekacin, sitafloxacin, and rifabutin may be possible therapeutic options for RGM infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.